thrombin inhibitor flovagatran (Trigen Laboratories)
90
Structured Review
Trigen Laboratories
thrombin inhibitor flovagatran
Thrombin Inhibitor Flovagatran, supplied by Trigen Laboratories, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/flovagatran/flovagatran/pm29391126-82-30-50
Average 90 stars, based on 1 article reviews
Thrombin Inhibitor Flovagatran, supplied by Trigen Laboratories, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/flovagatran/flovagatran/pm29391126-82-30-50
Average 90 stars, based on 1 article reviews
thrombin inhibitor flovagatran - by Bioz Stars,
2026-10
90/100 stars
Images
Related Articles
other:Article Title: Therapeutic potential of boron-containing compounds. Article Snippet: Blood 106, 1863 (2005) http://abstracts.hematologylibrary.org/cgi/ Article Title: Small-molecule arginase inhibitors. Article Snippet: 1Moscow Institute of Physics & Technology (State University), 9 Institutskiy lane, Dolgoprudny city, Moscow Region, 141700, Russian Federation 2ChemDiv, 6605 Nancy Ridge Drive, San Diego, CA 92121, USA *Author for correspondence: Fax: +7 495 408 72 77 E-mail: yai@chemdiv.com Arginase is an enzyme that metabolizes l-arginine to l-ornithine and urea.. In addition to its fundamental role in the hepatic ornithine cycle, it also influences the immune systems in humans and mice.. Arginase participates in many inflammatory disorders by decreasing the synthesis of nitric oxide and inducing fibrosis and tissue regeneration. l-arginine deficiency, which is modulated by myeloid cell arginase, suppresses T-cell immune response. Article Title: Discontinued drugs in 2011: cardiovascular drugs. Article Snippet: On 19 September 2011, a new World Health Organization (WHO) report stated that cardiovascular diseases (CVDs) are the leading causes of death and disability in the world.. It is estimated that about 17.3 million people died from CVD in 2008 and over 80% of CVD deaths took place in lowand middle-income countries; almost 23.6 million people will die from CVD by 2030 [1].. The continued high rate of cardiovascular morbidity and mortality has attracted wide concern and great attention of pharmaceutical industry. |